18386-03-3

Basic information

• Product Name: 3-(3-BROMO-PHENOXY)-PROPIONIC ACID
• Synonyms: Propionicacid, 3-(m-bromophenoxy)- (8CI); 3-(3-Bromophenoxy)propanoic acid
• CAS NO: 18386-03-3
• Molecular Formula: C₉H₉BrO₃
• Molecular Weight: 245.07
• Mol File: 18386-03-3.mol

Chemical Properties

• Boiling Point: 321.4°Cat760mmHg
• Flash Point: 148.2°C
• Appearance: /
• Density: 1.558g/cm³
• Vapor Pressure: 0.000123mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 3-(3-BROMO-PHENOXY)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-BROMO-PHENOXY)-PROPIONIC ACID(18386-03-3)
• EPA Substance Registry System: 3-(3-BROMO-PHENOXY)-PROPIONIC ACID(18386-03-3)

Safety Data

• Hazardous Substances Data: 18386-03-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H9BrO3/c10-7-2-1-3-8(6-7)13-5-4-9(11)12/h1-3,6H,4-5H2,(H,11,12)

Upstream product

• 107-94-8 chloropropionic acid 
• 591-20-8 3-Bromophenol 
• 57-57-8 β-Propiolactone 
• 1016736-70-1 3-(3-bromophenoxy)propanenitrile 
• 590-92-1 3-Bromopropionic acid 
• 92584-63-9 3-(3-bromophenoxy)propan-1-ol 

Downstream Products

• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 
• 168759-60-2 7-bromo-4H-benzopyran-4-one 
• 1260485-23-1 5-bromochromone 
• 1199782-67-6 5-bromo-4-chromanone 
• 129789-91-9 3-(3-bromo-phenoxy)-propionic acid ethyl ester 
• 1429323-80-7 C₁₇H₂₅BO₅ 
• 1429323-81-8 C₃₄H₄₇N₅O₉ 
• 1429323-82-9 C₁₇H₁₉N₅O₃ 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Acid activated montmorillonite K-10 mediated intramolecular acylation: Simple and convenient synthesis of 4-chromanones

3-Aryloxyproionic acids undergo intramolecular cyclization in the presence of AA.Mont.K-10 in toluene under reflux for 30–45 min in good to excellent yields. Phenyl ring bearing various substituents at the ortho, meta, para positions undergo this cyclization reaction. This method involves simple work up and amenable for large scale preparations. The heterogeneous acid treated catalyst can be regenerated and used for up to three cycles with minimum loss of activity.

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

PPAR (peroxisome proliferator-activated receptor) agonist and application thereof to treatment of senile dementia and other diseases

The invention relates to a compound, namely a gamma-subtype peroxisome proliferator-activated receptor (PPAR) agonist. In addition, the invention discloses a medicinal component and a preparation containing the compound and application of such the gamma-subtype PPAR agonist.

ARYL SULFONAMIDES AS BLT1 ANTAGONISTS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leu

ARYL SULFONAMIDES AS BLT1 ANTAGONISTS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leu

Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA

Enoyl acyl carrier protein reductase (ENR) is an essential type II fatty acid synthase (FAS-II) pathway enzyme that is an attractive target for designing novel antitubercular agents. Herein, we report sixty-eight novel pyrrolyl substituted aryloxy-1,3,4-thiadiazoles synthesized by three-step optimization processes. Three-dimensional quantitative structure-activity relationships (3D-QSAR) were established for pyrrolyl substituted aryloxy-1,3,4-thiadiazole series of InhA inhibitors using the comparative molecular field analysis (CoMFA). Docking analysis of the crystal structure of ENR performed by using Surflex-Dock in Sybyl-X 2.0 software indicates the occupation of pyrrolyl substituted aryloxy 1,3,4-thiadiazole into hydrophobic pocket of InhA enzyme. Based on docking and database alignment rules, two computational models were established to compare their statistical results. The analysis of 3D contour plots allowed us to investigate the effect of different substituent groups at different positions of the common scaffold. In vitro testing of ligands using biological assays substantiated the efficacy of ligands that were screened through in silico methods.

MACROCYCLIC LRRK2 KINASE INHIBITORS

The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease

NOVEL ARYL UREA DERIVATIVE

There is a need for FAAH inhibitors capable of oral administration and having excellent efficacy, particularly agents for the prevention and treatment of pain. Disclosed are novel arylurea compounds represented by formula (I), salts or solvates thereof, and pharmaceutical compositions comprising the same as an active ingredient. The pharmaceutical composition is used primarily for FAAH inhibitors, or agents for prevention and treatment of pain.

Efficient synthesis of chromones with alkenyl functionalities by the heck reaction

The usefulness of the Heck reaction in the field of chromones has been demonstrated. Bromochromones with the halogen atom in their rings A and B were reacted with various terminal alkenes to give hitherto unknown alkenyl-substituted chromones. Reactivity of the substrates was found to markedly depend on the position of the bromine atom. Under phosphine-free conditions using a phase-transfer catalyst additive (tetrabutylammonium bromide), shorter reaction periods and usually higher yields were obtained.